Radiosynthesis of (S)-2-(2-[¹⁸F]fluoroethoxy)-4-([3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl)-benzoic acid ([¹⁸F]repaglinide)

B. Wängler¹, S. Schneider², O. Thews³, E. Schirrmacher¹, S. Comagic¹, P. Feilen², C. Schwanstecher⁴, M.

Schwanstecher⁴, C.-Y. Shiue⁵, A. Alavi⁵, S. Höhnemann¹, M. Piel¹, F. Rösch¹ and R. Schirrmacher¹

¹Institute of Nuclear Chemistry, Johannes Gutenberg-University of Mainz, Fritz-Strassmann-Weg 2, D-55128 Mainz,


Germany, ²1. Med. Clinic, Division of Endocrinology and Metabolic Disease, Johannes Gutenberg-University of

Mainz, D-55131, Germany, ³Institute of Physiology and Pathophysiology, Johannes Gutenberg-University Mainz,

Germany ⁴Institute of Pharmacology and Toxicology, University of Braunschweig, Braunschweig, Germany,

⁵Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA

Introduction: Diabetes mellitus comprises a heterogeneous group of disorders characterized by high blood glucose levels. Two major types of diabetes mellitus have been defined: type 1- and type 2 diabetes. Repaglinide is the first member of the carbamoylmethylbenzoic acid chemical family to be used in a clinical setting, being a new chemical class of insulin secretagogues with an insulin release profile which is very different to sulfonylureas like Glyburide. If biological activity is retained, a ¹⁸F-labeled repaglinide derivative with high specific activity might become a valuable tool for the visualization and quantification of human pancreatic β -cell mass *in vivo*.



Aim: The aim was to synthesize the ¹⁸F-labeled nonsulfonylurea hypoglycemic agent (S)-2-(2-[¹⁸F]fluoroethoxy)-4-((3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl-

carbamoyl)-methyl)-benzoic acid ($[^{18}F]$ repaglinide), a derivative of the sulfonylurea-receptor (SUR) ligand repaglinide, for the non-invasive investigation of the sulfonylurea 1 receptor status of pancreatic beta-cells by positron emission tomography (PET) in the context of type 1 and type 2 diabetes.

Radiochemistry: No-carrier-added (NCA) aqueous [¹⁸F]fluoride (18000 MBq) prepared by the ¹⁸O(p,n)¹⁸F nuclear reaction on an enriched water (95 %) target was added to a solution of 1 N K2CO3 (15 μ l) and Kryptofix 2.2.2. (10-15 mg) in CH3CN (800 μ L). The water was removed by coevaporation to dryness with CH3CN (2 x 1 mL) using a stream of nitrogen at 80°C.

To the dried Kryptofix 2.2.2./[¹⁸F]fluoride complex (17000 MBq) in acetonitrile (1 mL) ethylenglycol-1,2-ditosylate (8-10 mg, 20-25 μ mol) was added and heated under stirring in a sealed vial for 3 min. Purification of the crude product was accomplished using HPLC (acetonitrile/water, 50:50, flow rate: 5 mL/min rt: 8 min). After diluting the HPLC fraction containing the 2-[¹⁸F]fluoroethyltosylate with water (20 mL), the product was loaded on a C18-SepPac cartridge (Waters), dried with nitrogen gas and eluted with tempered (25-30°C) diethyl ether (2 mL) to yield the desired product 2-[¹⁸F]fluoroethyltosylate with an activity of 8000 MBq. After evaporation of the diethyl ether in a stream of nitrogen, the 2-[¹⁸F]fluoroethyltosylate was taken up in DMSO (150-200 μ L).

(S)-2-(2-[¹⁸F]Fluoroethoxy)-4-([3-methyl-1-(2-piperidin-1yl-phenyl)-butylcarbamoyl]-methyl)-benzoic acid

To the precursor (3 mg, 6.8 µmol) dissolved in DMSO (250 µL) 1 N NaOH solution was added (6.8 µL, 6.8 µmol) and the mixture was heated at 150°C for 2 min. A solution of 2- $[^{18}F]$ fluoroethyltosylate (8000 MBq) in DMSO (150–200 µL) was added and stirred in a sealed reaction vessel at 150°C for 10 min. The product was purified with HPLC (acetonitrile/0.1 M acetic acid/sodium acetate buffer (pH = 6) (8/2) (v/v), flow rate 4 mL/min, tr = 10.2 min). After diluting the HPLC fraction containing the product with water (20 mL), it was loaded on a C18-SepPac cartridge (Waters), dried with nitrogen and eluted with methanol (1.5 mL) to yield (S)-2(-[¹⁸F]fluoroethoxy)-4-([3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl)-benzoic acid methyl ester.

1 N NaOH solution was added (100 μ L) and stirred in a sealed reaction vessel at 80°C for 35 min. The mixture was neutralized with 1 N HCl (100 uL). The product was purified with HPLC (acetonitrile/0.1 M acetic acid/sodium acetate buffer (pH = 6) (8/2) (v/v), flow rate 4 mL/min, tr = 4.5 min). After diluting the HPLC fraction containing the product with water (20 mL), it was loaded on a C18-SepPac cartridge (Waters), dried with nitrogen and eluted with warm ethanol (1 mL) to yield 1500 MBq of the product. HPLC analysis showed a radiochemical purity of >98%. Radio-TLC analysis confirmed the results (ethylacetate/methanol 9:1, Rf = 0.7). The specific activity of (S)-2-(2-[18F]fluoro-ethoxy)-4-((3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl-carbamoyl)-methyl)-benzoic acid ([¹⁸F]repaglinide) was between 50 and 60 GBq/µmol as determined via a UV-calibration curve.